Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 6/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439077 | 1.00 | HSD17B2 (0.46) | HSD17B2HSD17B1PPARGAOC3SIRT2 | |
| SCHEMBL3439063 | 0.90 | HSD17B2 (0.49) | HSD17B2HSD17B1PPARGAOC3SIRT2 | |
| SCHEMBL3439062 | 0.90 | HSD17B2 (0.49) | HSD17B2HSD17B1PPARGAOC3SIRT2 | |
| SCHEMBL3439125 | 0.84 | PPARG (0.57) | PPARG | |
| SCHEMBL3439215 | 0.84 | PPARG (0.57) | PPARG | |
| SCHEMBL3439127 | 0.84 | PPARG (0.57) | PPARG | |
| SCHEMBL6478851 | 0.83 | HSD17B2 (0.54) | HSD17B2HSD17B1AOC3MEN1KMT2A | |
| SCHEMBL3439078 | 0.82 | TP53 (0.41) | PPARGMEN1KMT2ATP53HCAR2 | |
| SCHEMBL3439079 | 0.82 | TP53 (0.41) | PPARGMEN1KMT2ATP53HCAR2 | |
| SCHEMBL6186838 | 0.82 | HSD17B2 (0.53) | HSD17B2HSD17B1AOC3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | HSD17B2 448/4885HSD17B1 321/4885PPARG 1/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | HSD17B2 448/4885HSD17B1 321/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.